Last reviewed · How we verify
Pancreatic Enzyme
Pancreatic enzymes replace or supplement the natural digestive enzymes (amylase, lipase, protease) that the pancreas fails to produce adequately.
Pancreatic enzymes replace or supplement the natural digestive enzymes (amylase, lipase, protease) that the pancreas fails to produce adequately. Used for Pancreatic exocrine insufficiency secondary to chronic pancreatitis, Pancreatic exocrine insufficiency in cystic fibrosis, Pancreatic exocrine insufficiency following pancreatic surgery or pancreatic cancer.
At a glance
| Generic name | Pancreatic Enzyme |
|---|---|
| Also known as | CREON, Creon |
| Sponsor | University of Oxford |
| Drug class | Pancreatic enzyme replacement therapy (PERT) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Pancreatic enzyme replacement therapy (PERT) provides exogenous pancreatic enzymes to compensate for pancreatic insufficiency, enabling proper digestion of fats, proteins, and carbohydrates in the small intestine. This restores nutrient absorption and reduces malabsorption symptoms in patients with chronic pancreatitis, cystic fibrosis, pancreatic cancer, or post-surgical pancreatic dysfunction.
Approved indications
- Pancreatic insufficiency secondary to chronic pancreatitis
- Cystic fibrosis-related pancreatic insufficiency
- Post-pancreatic surgery pancreatic insufficiency
- Pancreatic cancer-related malabsorption
Common side effects
- Abdominal pain or cramping
- Diarrhea
- Constipation
- Nausea
- Hyperuricemia (with high-dose use)
Key clinical trials
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer (NA)
- Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer (PHASE2)
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (PHASE3)
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2, PHASE3)
- The Effect of PPI on Endoscopic Treatment of WON: a Multicenter Randomized Controlled Trial. (NA)
- Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (PHASE2)
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pancreatic Enzyme CI brief — competitive landscape report
- Pancreatic Enzyme updates RSS · CI watch RSS
- University of Oxford portfolio CI